Trials / Completed
CompletedNCT06976372
A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity
A Phase 1, Randomized, Double-blind, Multiple-dose Study to Evaluate the Pharmacokinetics of AMG 133 Administered Subcutaneously in Subjects With Overweight or Obesity
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the pharmacokinetics (PK) of AMG 133 after multiple subcutaneous (SC) administrations in participants with overweight or obesity using various dose regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 133 | AMG 133 will be administered SC. Dose levels range from A to D lowest to highest. |
Timeline
- Start date
- 2024-08-20
- Primary completion
- 2024-12-27
- Completion
- 2024-12-27
- First posted
- 2025-05-16
- Last updated
- 2025-10-08
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06976372. Inclusion in this directory is not an endorsement.